Abstract: The prevalence of hyperandrogenism has been reported to be increased in reproductive-age women with type-1 diabetes (T1DM). This observation however is based on findings using inaccurate immunoassays. No studies have been reported in diabetes using liquid-chromatography-mass-spectrometry (LCMS). We compared LCMS-measured androgens in T1DM-women with age-/ BMI-matched normal women, and compared findings with those in women with type-2 diabetes (T2DM) also compared to a matched control group (Table Below). Compared to non-diabetic women, androstenedione and SHBG were greater in T1DM while estimated free-testosterone was lower. In contrast, compared to non-diabetic women, androstenedione, DHEA-OX and SHBG levels were lower in T2DM while free-testosterone and DHEAS were greater. Total testosterone did not differ between groups in either comparison. T1DM and T2DM are associated with differing effects on androgen levels. These differences are likely to reflect differences in insulin sensitivity and differing effects of exogenous insulin administration. Their clinical significance requires further investigation.
Mean (± SEM); P-value vs matched non-diabetic.
Median (range); P-value vs matched non-diabetic.
|TID (N=63; median age =32; median BMI=25.5)||Non-diabetic (N=42; median age =34.5; median BMI=27.4)||T2D TID (N=32; median age =38; median BMI=36)||Non-diabetic (N=55; median age =34; median BMI=35.1)|
|Androstendione (nM)||5.1 (1.413.1) P=0.0005||3.6 (0.016.9)||2.5 (0.014.1) P=0.0035||3.8 (0.415.5)|
|DHEA-OX (nM)||10.1 (2.044.0)||12.0 (1.343.7)||5.7 (0.015.3) P <0.0001||13.5 (1.151.0)|
|DHEAS (uM)||5 (1.314.3)||5.0 (1.114.7)||6.0 (2.213.9) P=0.0045||4.3 (1.313.1)|
|FT (%)||1.1 (± SEM 0.05) P=0.0015||1.4 (± SEM 0.07)||2.0 (± SEM 0.11) P=0.0005||1.6 (± SEM 0.056)|
20 - 23 May 2017
European Society of Endocrinology